相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy
Giuseppe Minniti et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2011)
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study
Young-Hoon Kim et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
Oliver Grauer et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anaplastic Gliomas
Lisa M. DeAngelis
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
Jerzy Hildebrand et al.
EUROPEAN JOURNAL OF CANCER (2008)
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors
Stephanie E. Combs et al.
RADIOTHERAPY AND ONCOLOGY (2008)
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404
MD Prados et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy -: a phase-II study
C Wismeth et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Effects of a novel synthetic retinoid on malignant glioma in vitro:: inhibition of cell proliferation, induction of apoptosis and differentiation
SL Costa et al.
EUROPEAN JOURNAL OF CANCER (2001)
Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines
H Bouterfa et al.
NEUROSURGERY (2000)
分享论文
